RecruitingPhase 2NCT07063212
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
Studying Squamous cell carcinoma of the hypopharynx
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Principal Investigator
- Winston Wong, MD, MDMemorial Sloan Kettering Cancer Center
- Intervention
- Sacituzumab Govitecan(drug)
- Enrollment
- 40 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2028
Study locations (7)
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
- Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities), Commack, New York, United States
- Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York, New York, United States
- Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States
Collaborators
Gilead Sciences
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07063212 on ClinicalTrials.govOther trials for Squamous cell carcinoma of the hypopharynx
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06761937Thermoradiotherapy for Locally Advanced Head and Neck Cancer PatientsErasmus Medical Center
- RECRUITINGPHASE3NCT06706401Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck CarcinomaCentre Leon Berard
- RECRUITINGNCT06380686Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and OutcomeAIO-Studien-gGmbH
- RECRUITINGPHASE3NCT06525220A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)Merus B.V.
- RECRUITINGPHASE3NCT05333523Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study.Radboud University Medical Center
- RECRUITINGPHASE2NCT04858269First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma PatientsWake Forest University Health Sciences
- ACTIVE NOT RECRUITINGPHASE3NCT04590963Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck CancerAstraZeneca
- RECRUITINGPHASE2, PHASE3NCT01810913Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck CancerNational Cancer Institute (NCI)
See all trials for Squamous cell carcinoma of the hypopharynx →